View Older Stories View More Recent Stories

Sep 4, 2025 07:00AM Atlas Venture Announces $400 Million Third Opportunity Fund
Sep 4, 2025 06:31AM Form D Atlas Venture Opportunit
Aug 26, 2025 06:02AM Form N-PX Atlas Venture Life Scien For: Jun 30
Aug 22, 2025 04:30PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Aug 22, 2025 04:25PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 15, 2025 07:17PM Form SCHEDULE 13D/A Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 14, 2025 04:32PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Aug 14, 2025 04:24PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 13, 2025 04:26PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Aug 13, 2025 04:24PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Aug 12, 2025 04:49PM Form 13F-HR Atlas Venture Life Scien For: Jun 30
Aug 7, 2025 05:12PM Form SCHEDULE 13D/A Vigil Neuroscience, Inc. Filed by: Atlas Venture Fund XII, L.P.
Aug 7, 2025 05:00PM Form 4 Vigil Neuroscience, Inc. For: Aug 05 Filed by: Atlas Venture Fund XII, L.P.
Aug 7, 2025 08:00AM K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical Trial Collaboration
Aug 5, 2025 04:32PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Aug 5, 2025 04:25PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 30, 2025 04:18PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 30, 2025 04:15PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 30, 2025 08:00AM Be Bio Announces First Participant Dosed in BeCoMe-9 Trial of BE-101 in Hemophilia B
Jul 29, 2025 04:54PM Form SCHEDULE 13D/A ImageneBio, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 25, 2025 09:07AM Form 13F-NT Atlas Venture Associates For: Jun 30
Jul 25, 2025 09:04AM Form 13F-NT Atlas Venture Associates For: Jun 30
Jul 25, 2025 09:03AM Form 13F-NT Atlas Venture Fund VIII, For: Jun 30
Jul 25, 2025 09:00AM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Jul 24, 2025 04:28PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 24, 2025 04:26PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 23, 2025 04:30PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 23, 2025 04:26PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 18, 2025 04:34PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Jul 18, 2025 04:31PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 10, 2025 06:30AM Renasant Bio Launches to Pioneer Next-Generation Disease-Modifying Small Molecule Treatments for ADPKD
Jun 25, 2025 05:37PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Fund XII, L.P.
Jun 25, 2025 05:32PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Associates XII, L.P.
Jun 24, 2025 05:03PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Fund XII, L.P.
Jun 24, 2025 04:59PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Associates XII, L.P.
Jun 11, 2025 08:41AM Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025
Jun 10, 2025 08:00AM Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases
Jun 6, 2025 06:30AM Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
May 29, 2025 07:30AM Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
May 21, 2025 08:00AM Rectify Pharma to Present Translational Data on Novel Approach to Treat Chronic Kidney Disease and Vascular Calcification at ERA 2025
May 17, 2025 08:00AM Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia
May 14, 2025 04:15PM Form 13F-HR Atlas Venture Life Scien For: Mar 31
May 9, 2025 06:00AM Rectify Pharma Presents Translational Data for Novel Positive Functional Modulator Demonstrating Improved Biliary and Liver Health at EASL 2025
May 8, 2025 11:01AM Form 13F-NT Atlas Venture Associates For: Mar 31
May 8, 2025 10:58AM Form 13F-NT Atlas Venture Associates For: Mar 31
May 8, 2025 10:53AM Form 13F-NT Atlas Venture Fund VIII, For: Mar 31
May 8, 2025 10:48AM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 6, 2025 05:15PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Associates XII, L.P.
May 6, 2025 05:11PM Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Fund XII, L.P.
Apr 30, 2025 04:29PM Form SCHEDULE 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
View More Recent Stories View Older Stories